☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
ARVO
Samsung Bioepis Presents Results of SB11 (proposed biosimilar ranibizumab) at ARVO 2021
May 3, 2021
Novartis Presents Results of Beovu (brolucizumab -dbll) in P-III KESTREL and KITE Studies for Diabetic Macular Edema at ARVO2021
May 3, 2021
Insights+: The US FDA New Drug Approvals in July 2023
August 16, 2023
Pfizer Reports the US FDA Acceptance of BLA for Fidanacogene Elaparvovec to Treat Hemophilia B
June 28, 2023
Belite Bio Presents 18-Month Interim Results from P-II Study (LBS-008-CT02) of Tinlarebant for Stargardt Disease at ARVO 2023
April 26, 2023
Samsung Bioepis Presents 52 Weeks P-III Study Results of SB15, Proposed biosimilar to Eylea (aflibercept) for Neovascular Age-Rela...
April 25, 2023
Bettina Cockroft, SVP & CMO at Sangamo Therapeutics Shares Insights from the Positive P-I/II Data for Fabry Disease Treatment
April 24, 2023
PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency
March 24, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.